1	INDICATIONS AND USAGE
CRESTOR is an HMG CoA reductase inhibitor indicated for:
patients with primary hyperlipidemia and mixed dyslipidemia as an adjunct to diet to reduce elevated totalC, LDLC, ApoB, nonHDLC, and TG levels and to increase HDLC (1.1)
patients with hypertriglyceridemia as an adjunct to diet (1.2)
patients with primary dysbetalipoproteinemia (TypeIII hyperlipoproteinemia) as an adjunct to diet (1.3)
patients with homozygous familial hypercholesterolemia (HoFH) to reduce LDLC, total-C, and ApoB
(1.4)
slowing the progression of atherosclerosis as part of a treatment strategy to lower totalC and LDLC as an adjunct to diet (1.5)
pediatric patients 10to17years of age with heterozygous familial hypercholesterolemia (HeFH) to reduce elevated totalC, LDLC and ApoB after failing an adequate trial of diet therapy (1.1)
risk reduction of MI, stroke, and arterial revascularization procedures in patients without clinically evident CHD, but with multiple risk factors (1.6)
Limitations of use (1.7):
CRESTOR has not been studied in Fredrickson Type I and V dyslipidemias.
1.1 Hyperlipidemia and Mixed Dyslipidemia
CRESTOR is indicated as adjunctive therapy to diet to reduce elevated Total-C, LDL-C, ApoB, nonHDLC, and triglycerides and to increase HDLC in adult patients with primary hyperlipidemia or mixed dyslipidemia. Lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when response to diet and nonpharmacological interventions alone has been inadequate.
Pediatric Patients 10to17 years of age with Heterozygous Familial Hypercholesterolemia (HeFH)
Adjunct to diet to reduce TotalC, LDLC and ApoB levels in adolescent boys and girls, who are at least one year post-menarche, 1017 years of age with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: LDLC> 190 mg/dL or >160 mg/dL and there is a positive family history of premature cardiovascular disease (CVD) or two or more other CVD risk factors.
1.2 Hypertriglyceridemia
CRESTOR is indicated as adjunctive therapy to diet for the treatment of adult patients with hypertriglyceridemia.
1.3 Primary Dysbetalipoproteinemia (Type III Hyperlipoproteinemia)
CRESTOR is indicated as an adjunct to diet for the treatment of patients with primary dysbetalipoproteinemia (TypeIIIHyperlipoproteinemia).
1.4 Homozygous Familial Hypercholesterolemia
CRESTOR is indicated as adjunctive therapy to other lipid-lowering treatments (e.g., LDL apheresis) or alone if such treatments are unavailable to reduce LDLC, TotalC, and ApoB in adult patients with homozygous familial hypercholesterolemia.
1.5 Slowing of the Progression of Atherosclerosis
CRESTOR is indicated as adjunctive therapy to diet to slow the progression of atherosclerosis in adult patients as part of a treatment strategy to lower TotalC and LDLC to target levels.
1.6 Primary Prevention of Cardiovascular Disease
In individuals without clinically evident coronary heart disease but with an increased risk of cardiovascular disease based on age 50 years old in men and 60 years old in women, hsCRP2 mg/L, and the presence of at least one additional cardiovascular disease risk factor such as hypertension, low HDLC, smoking, or a family history of premature coronary heart disease, CRESTOR is indicated to:
reduce the risk of stroke
reduce the risk of myocardial infarction
reduce the risk of arterial revascularization procedures
1.7 Limitations of Use
CRESTOR has not been studied in Fredrickson TypeI and V dyslipidemias.